Annual verification report on the deposit and use of raised funds
Zhong Hui Hui Hui Jian [2022] No. 1102 Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) all shareholders:
We have verified the attached special report on the deposit and use of raised funds in 2021 prepared by the management of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) (hereinafter referred to as Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) company).
1、 Restrictions on the users and purposes of the report
This assurance report is only used for the disclosure of the annual report of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) company and shall not be used for any other purpose. We agree to take this assurance report as a necessary document of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) company’s annual report, submit it together with other documents and disclose it to the public.
2、 Responsibilities of management
The responsibility of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) company’s management is to provide true, legal and complete relevant materials, prepare the special report on the deposit and use of raised funds in 2021 in accordance with the guidelines for the application of self regulatory rules for companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation and relevant format guidelines, and ensure that its content is true, accurate and complete without false records, misleading statements or major omissions.
3、 Responsibilities of Certified Public Accountants
Our responsibility is to put forward the assurance conclusion on the special report on the deposit and use of raised funds in 2021 prepared by the management of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) company on the basis of the implementation of the assurance work.
4、 Job overview
We have carried out the assurance business in accordance with the provisions of other assurance business standards for Chinese certified public accountants No. 3101 – assurance business other than audit or review of historical financial information. The standard requires us to plan and implement assurance work to obtain reasonable assurance on whether the information of the assurance object is free from material misstatement. In the assurance process, we have implemented audit procedures that we consider necessary, including understanding, inspection and verification. We believe that our assurance work provides a reasonable basis for expressing opinions.
5、 Assurance conclusion
We believe that the special report on the deposit and use of raised funds in 2021 prepared by the management of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) company complies with the provisions of the guidelines for the application of self regulatory rules for companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation and relevant format guidelines, and truthfully reflects the actual deposit and use of raised funds of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) company in 2021.
(there is no text on this page, which is the signature and seal page of the verification report on the deposit and use of raised funds in Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) 2021)
Zhonghui Certified Public Accountants (special general partnership) Chinese certified public accountant: Huang Ping
(project partner)
China Certified Public Accountant: Huang Chanjuan
Chinese certified public accountant: Fanggang
Report date: March 28, 2022
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513)
Special report on the deposit and use of raised funds in 2021
Shanghai Stock Exchange:
In accordance with the requirements of the guidelines for the application of self regulatory rules for companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation and relevant format guidelines issued by your office, the company’s deposit and use of raised funds in 2021 are specially explained as follows: I. Basic information of raised funds
（1） Actual amount of raised funds and arrival time of funds
The company was approved to register in the reply on approval of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) initial public offering registration (zjxk [2020] No. 1584) issued by the China Securities Regulatory Commission, and issued 30.09 million RMB ordinary shares (A shares) to the public at the issue price of RMB 44.36 per share. The total amount of funds raised was RMB 133479240000, after deducting the issuance expenses (excluding tax) of RMB 11208398349, The net amount of funds raised this time is 122270841651 yuan. The availability of the above raised funds has been verified by Zhonghui Certified Public Accountants (special general partnership), which issued the capital verification report (Zhonghui kuaiyan [2020] No. 5681) 1 on August 26, 2020.
（2） Use and balance of raised amount
As of December 31, 2021, the balance of raised funds (including the net amount of interest income deducting bank charges) is
2484336 million yuan.
The details are as follows (unit: RMB 10000):
Project amount
Total raised funds 13347924 less: brokerage underwriting Commission and recommendation fee 909118 total received raised funds 12438806 less: amount of self raised funds invested in advance replaced by raised funds 1066929 minus: 726.00 of the amount paid in advance for the issuance expenses replaced by the raised funds minus: 139121 of the amount paid for the issuance expenses excluding tax minus: 5806423 of the amount directly invested in the raised projects
1. The difference between the net raised funds of 122270841651 yuan in this assurance report and 122270065941 yuan in the capital verification report is 775710 yuan, which is the difference between the planned issuance expenses and the actual situation: 1 The actual issuance report production cost is 943393 yuan lower than expected; 2. The actual stamp duty is 167683 yuan higher than expected.
Project amount
Minus: balance of 3140000 yuan for purchasing financial products, time deposits and structured deposits plus: net amount of 270603 yuan deducted from accumulated income and interest income of financial products, time deposits and structured deposits and handling charges, balance of raised funds on December 31, 20212484336 yuan
2、 Management of raised funds
（1） Management of raised funds
According to the law of the people’s Republic of China on the protection and management of the interests of listed companies, and the law of the people’s Republic of China on the supervision and administration of the use of funds raised by listed companies, No. 2, the law on the protection and management of the interests of listed companies, and the law of the people’s Republic of China on the supervision and administration of the use of funds raised by listed companies The company has formulated the measures for the administration of raised funds (hereinafter referred to as the measures) in accordance with the provisions of relevant laws, regulations and normative documents such as the rules for the listing of shares on the science and Innovation Board of Shanghai Stock Exchange (revised in December 2020), the guidelines for the application of self regulatory rules for companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, and in combination with the actual situation of the company. According to the management measures, the company has adopted a special account storage system for the funds raised, set up a special account for the funds raised in the bank, and along with the sponsor, the Tsingtao Brewery Company Limited(600600) 60030 chengduqingyang Industrial Park sub branch Bank Of China Limited(601988) Tianfu New Area Huayang sub branch signed the three (four) party supervision agreement for raised funds, which defined the rights and obligations of all parties. There is no significant difference between the three (4) party supervision agreement and the model three (4) party supervision agreement of Shanghai Stock Exchange. The company has strictly followed and performed the raised funds in order to facilitate the management and use of the raised funds and supervise their use, so as to ensure the special use of funds.
（2） Special account storage of raised funds
As of December 31, 2021, the company has 8 special accounts for raised funds and 1 special account for financial management of raised funds
The fund storage is as follows (unit: RMB 10000):
Deposit bank account number account category storage balance remarks
China Construction Bank Corporation(601939) 510501426295 Shenzhen Fountain Corporation(000005) 43 special account for raised funds 543799 current account
Chengdu Qingyang Industrial Park sub branch
Bank Of Chengdu Co.Ltd(601838) Fangcao sub branch 100130 China High-Speed Railway Technology Co.Ltd(000008) 0290 special account for raised funds 167446 current account
China Citic Bank Corporation Limited(601998) Chengdu Shuhan sub branch 8111001013200676400 special account for raised funds 26.33 current account
Agricultural Bank Of China Limited(601288) 2289230104 Dongrui Food Group Co.Ltd(001201) 8 special account for raised funds 16.41 current account
Chengdu Jinsha Xiyuan sub branch
China Citic Bank Corporation Limited(601998) Chengdu Yingbin Avenue sub branch 8111001013900674850 special account for raised funds – cancelled on October 15, 2021
Deposit bank account number account category storage balance remarks
Bank Of China Limited(601988) Tianfu New Area Huayang sub branch 117217817048 special account for raised funds 1158859 current account
China Citic Bank Corporation Limited(601998) Chengdu Shuhan sub branch 8111001012400676405 special account for raised funds 116.40 current account
Industrial And Commercial Bank Of China Limited(601398) 44029220191 Huafon Chemical Co.Ltd(002064) 67 special account for raised funds 61.02 current Chengdu Gaoxin Yongfeng Road sub branch
China Citic Bank Corporation Limited(601998) Chengdu 8111001012400779719 special account for raised funds 127918 current Zijing sub branch
Bank of Dalian Co., Ltd. Chengdu 116727 Shenzhen Properties & Resources Development (Group) Ltd(000011) 16 raised funds 464298 special account for current branch financial management
Total — 2484336-
3、 Actual use of raised funds this year
（1） Use of funds for investment projects with raised funds
See Appendix 1 of this report for the comparison table of the use of raised funds in 2021.
（2） Advance investment and replacement of investment projects with raised funds
On September 25, 2020, the company held the 13th meeting of the second board of directors and the 9th meeting of the second board of supervisors, deliberated and approved the proposal on using raised funds to replace self raised funds invested in projects invested with raised funds in advance and paid issuance expenses, and agreed to use raised funds to replace 7.26 million yuan of paid issuance expenses and 1066929 million yuan of self raised funds invested in projects invested with raised funds in advance, The total is 1139529 million yuan. The replacement amount has been verified by Zhonghui Certified Public Accountants (special general partnership) and issued on September 16, 2020
